CDK4 and central nervous system cancer: And CDK4-overexpressing glioma cells were found to be absolutely resistant to CDK4/6i.[25] In the PALOMA-2 study, CDK4 and CDK6 expression was not significantly associated with pabociclib and letrozole treatment.